Prostaglandins (PGs) are lipid mediators that participate in the regulation of immunological and inflammatory responses, and PG production can affect viral replication. In this study, we have investigated the mechanism of PGE2 production in airway epithelial cells, following respiratory syncytial virus (RSV) infection, and its role in viral replication. We show that RSV infection strongly induces PGE2 secretion, in a time-and replication-dependent manner, through increased cyclooxygenase-2 (COX-2) expression, which occurs independently from viral or cellular protein synthesis. RSV infection induces arachidonic acid release through induction of cytoplasmic phospholipase A 2 (cPLA 2 ) enzymatic activity and its membrane translocation. Specific inhibitors of cPLA 2 significantly block RSV-induced PGE2 secretion, indicating a key role of cPLA 2 in viral-induced PG production. Blocking PG secretion, through cPLA 2 or COX-2 inhibition, results in impairment of RSV replication and subsequent RSV-mediated epithelial cell responses, suggesting that inhibition of PG secretion could be beneficial in RSV infection by reducing proinflammatory mediator production. D
Introduction
Prostaglandins (PGs) are ubiquitous fatty acid derivatives produced by a variety of tissues and cell types and participate in the regulation of both physiological and pathophysiological processes. Normal physiological processes include regulation of renal function, vasomotor tone, platelet aggregation and blood clotting, differentiation of immune cells, wound healing, nerve growth, bone metabolism, ovulation, and initiation of labor. Prostaglandins also participate in the regulation of immunological and inflam-matory responses. Production of prostaglandin E2 (PGE2) is markedly increased in response to a variety of stimuli including interleukin-1 (IL-1), tumor necrosis factor (TNF)a, antigen/antibody complexes, lipopolysaccharide (LPS), and infectious agents (Arias-Negrete et al., 1995; Corbett et al., 1993; Steer et al., 2003) . PGE2 often plays an immunosuppressive role during inflammatory responses, thus preventing overactivation of cellular immunity. For example, PGE2 is able to inhibit cytokine production, as well as T and B cell proliferation (Phipps et al., 1991) . A variety of DNA and RNA viruses have been shown to stimulate PGE2 production through cyclooxygenase (COX)-2 expression (Bartz et al., 2002; Nokta et al., 1996; Rossen et al., 2004) , although certain viruses, like Epstein -Barr virus, have been shown to suppress PGE2 secretion and COX-2 mRNA accumulation (Savard et al., 2000) . Respiratory syncytial virus (RSV), an enveloped negative-sense single-stranded RNA virus (Hall and McCarthy, 1995) , is a leading cause of epidemic respiratory tract illness in children in the US and worldwide, resulting in more than 100,000 hospital admissions annually in the US alone (Hall and McCarthy, 1995) . RSV infection results in the production of a variety of mediators involved in lung immune/inflammatory responses, like cytokines, chemokines, interferons, and upregulating adhesion molecules and MHC antigens on the surface of infected cells (reviewed in Garofalo and Haeberle, 2000) . Though RSV infection of the lung results in profound airway inflammation, it is not associated with robust and long-lasting immunological responses so that re-infection is common throughout life . Indeed, RSV infection has been shown to inhibit mononuclear cell responses, as well as lymphocyte proliferation (Franke et al., 1995; Keles et al., 1999) , possibly through PGE2 production (Keles et al., 1998 (Keles et al., , 1999 . RSV induction of PGE2 was demonstrated by infecting human cord blood macrophages (Midulla et al., 1993) and dendritic cells (Bartz et al., 2002) . When compared with influenza and parainfluenza virus, RSV was the strongest PGE2 inducer. In vivo studies, either in cattle experimentally infected with bovine RSV (Gershwin et al., 1989) or in infants positive for RSV infection (Sznajer et al., 2004) , have also shown increased levels of PGE2 in the plasma or endotracheal aspirates. Recently, Richardson et al. have shown PGE2 production and COX-2 expression in alveolar epithelial cells infected with RSV, as well as in the lungs of RSV-infected cotton rats (Richardson et al., 2005) . The latter study, however, did not address in depth the mechanism of RSV-induced PGE2 prostaglandin secretion and did not investigate the effect of inhibition of PGE2 production on RSV replication. Indeed, increased production of PGE2 has been shown to result in increased replication of many different types of viruses, including herpes, adenovirus, picorna viruses, and HIV, although PGE2 can inhibit viral replication of a few ones, such as adenovirus, parainfluenza, and measles (reviewed in Steer et al., 2003) . In this study, we show that alveolar epithelial cells are strong producers of PGE2 following RSV infection, in a time-and replication-dependent manner, through COX-2 mRNA expression and protein synthesis. RSV-induced COX-2 expression does not require either viral or cellular protein synthesis as it occurs in the presence of cycloheximide, an inhibitor of protein translation. RSV infection of airway epithelial cells induces arachidonic acid (AA) release by activation of cytoplasmic phospholipase A2 (cPLA 2 ), and specific inhibitors of cPLA 2 significantly block RSV-induced PGE2 secretion in A549 cells, indicating a key role of cPLA 2 in viral-induced prostaglandin production. Inhibition of PGE2 secretion, using either specific COX-2 or cPLA 2 inhibitors, results in significant impairment of RSV replication and therefore RSV-mediated airway epithelial cell responses, such as chemokine production, as well as transcription factor activation, suggesting that selective inhibition of PGE2 could be beneficial in RSV infection by dampening the secretion of proinflammatory mediators and possibly promoting stronger immunological responses.
Results

RSV infection induces PGE2 secretion through COX-2 expression in A549 cells
We and others have previously shown that airway epithelial cells, the target cells of RSV infection, play an important role in initiating mucosal immune/inflammatory responses by producing a variety of soluble factors, like cytokines, chemokines, interferons, etc., that regulate communication among cells of the immune system (Garofalo and Haeberle, 2000) . Since PGE2 levels have been shown to be elevated in children with severe RSV infection (Sznajer et al., 2004) , we investigated whether A549 cells, a lung carcinoma cell line that retains features of type II alveolar epithelial cells (Lieber et al., 1976; Smith, 1977) , were able to produce PGE2 following RSV infection. A549 cells is a widely accepted model for studying RSV -epithelial cell interactions (Fiedler et al., 1996; Jamaluddin et al., 1998) , and we have previously shown that these cells behave very similar to normal human airway epithelial cells, such as the small alveolar epithelial cells, in terms of chemokine/ cytokine gene expression, transcription factor, and signaling pathway activation following RSV infection Olszewska-Pazdrak et al., 1998; Casola et al., 2001a; Zhang et al., 2001; Pazdrak et al., 2002) . A549 cells were infected with purified RSV, and culture supernatants were harvested at different time post-infection (p.i.) to determine PGE2 secretion by ELISA. As shown in Fig. 1A , RSV exposure resulted in a time-dependent increased production of PGE2, starting as early as 6 h p.i., with maximal production at 36 h p.i., time after which infected cells started to loose viability. Addition of UV-inactivated virus, which is unable to replicate, did not induce PG production (data not shown).
The first event in eicosanoid production is the release of arachidonic acid (AA) by PLA 2 . COX enzymes catalyze the oxidation of AA to PGH2 which is then isomerized to various prostanoids, including PGE2. There are three known isoforms of COX (reviewed in Smith et al., 2000) . COX-1 and COX-2 are similar in size, substrate specificity, and kinetics but differ in distribution and expression. COX-1 is constitutively expressed by many cell types, and PGs produced by this isoform are involved in the regulation of several normal physiological functions (Smith et al., 2000) . While COX-2 is constitutively expressed in certain organs or tissues, such as brain, kidney, and testes, in most cell types, its expression is rapidly upregulated by a variety of stimuli, and it is responsible for inducible PG secretion (Smith et al., 2000) . Therefore, to determine whether increased PGE2 release was dependent on COX-2 activa-tion, A549 cells were infected with RSV for 24 h, in the absence or presence of various concentrations of two different COX-2 inhibitors, celecoxib and NS398 (Penning et al., 1997; Futaki et al., 1994) . Supernatants were then assayed for PGE2 secretion by ELISA. As shown in Fig.  1B , addition of 10 and 50 AM of either celecoxib or NS398 at the time of RSV infection completely blocked PGE2 production, indicating that COX-2 is the major enzyme responsible for viral-induced PGE2 secretion.
To determine whether COX-2 expression was induced in alveolar epithelial cells infected with RSV, total RNA was extracted from control and infected A549 cells at different times post-infection for analysis of steady-state level of COX-2 mRNA by Northern blot. A small increase in mRNA expression was first detected at 6 h p.i., with maximal induction at 24 h ( Fig. 2A ). There was no further increase in mRNA levels at later time points (data not shown). The upregulation of COX-2 mRNA was paralleled by an increase in COX-2 protein synthesis, investigated by Western blot analysis ( Fig. 2B ), indicating that COX-2 gene expression and protein synthesis are coupled in RSVinfected A549 cells. RSV infection of A549 cells is known to induce the release of cytokines, such as IL-1 and TNF (Patel et al., 1995) , which can affect COX-2 expression (Seibert et al., 1995) . To determine whether a soluble mediator or RSV replication directly was responsible for COX-2 induction, we assessed COX-2 expression in A549infected cells treated with cycloheximide, a protein translation inhibitor, which blocks both viral and cellular protein synthesis. As shown in Fig. 2C , RSV infection of A549 cells induced a 7-fold increase in COX-2 mRNA levels, compared to control cells, which was greatly enhanced by the presence of cycloheximide. These findings indicate that viral transcription/replication alone is sufficient to induce COX-2 expression and that neither viral nor cellular protein synthesis is required.
RSV infection induces AA release and cPLA 2 activation in alveolar epithelial cells
Since the precursor for PGE2 synthesis is AA, we determined whether RSV induced an increased release of AA from infected cells. A549 cells were labeled overnight with [ 3 H]AA and then infected with RSV for various lengths of time. Supernatants from control and infected cells were collected to determine total radioactivity released into the medium by scintillation counting. As shown in Fig. 3 , RSV-infected cells showed a significantly higher release of radiolabeled AA compared to control cells, suggesting phospholipase activation. PLA 2 s are ubiquitous enzymes that are present in most cells and tissues. Using functional criteria, PLA 2 are classified in three main types: secretory PLA 2 (sPLA 2 ), intracellular Ca 2+ -dependent PLA 2 (cPLA 2 ), and intracellular Ca 2+ -independent PLA 2 (iPLA 2 ) (reviewed in Steer et al., 2003; Balsinde et al., 1999) . While intracellular iPLA 2 seems to be mainly involved in membrane phospholipid remodeling, sPLA 2 and cPLA 2 release AA as precursor of the inflammatory eicosanoids. In cell types that lack sPLA 2 expression, cPLA 2 accounts for the vast majority of AA release during cellular activation and is the enzyme involved in receptor-activated signaling (Steer et al., 2003) . To determine whether cPLA 2 was involved in RSV-induced PGE2 production, we treated airway epithelial cells with various inhibitors, which block either sPLA 2 , both cPLA 2 and iPLA 2 , or cPLA 2 only. We then assessed PGE2 production at 24 h p.i. As shown in Fig. 4 , both MAPF, a specific inhibitor of cPLA 2 and iPLA 2 (Balsinde et al., 1999) , and pyrrophenone, a recently characterized cPLA 2 specific inhibitor (Ono et al., 2002; Seno et al., 2000) , greatly reduced RSV-induced PGE2 secretion, which was not affected by BPB, an inhibitor of sPLA 2 (Balsinde et al., 1999) , indicating that this enzyme is not involved in RSVinduced PGE2 production. Fig. 3 . AA release from RSV-infected cells. A549 cells were labeled with [ 3 H]AA for 15 h, and, after extensive washing, cells were infected with RSV. Supernatants from control and infected cells were collected at different time points after infection, and amount of radioactivity released into the medium was determined by scintillation counting. The experiment was performed in triplicate and repeated twice. Results are expressed as percent increase over control cells. Fig. 4 . Effect of various PLA 2 inhibitors on RSV-induced PGE2 production. A549 cells were infected with RSV in the absence or presence of 10 AM BPB, 25 AM MAPF, or 25 AM pyrrophenone (PP). Culture supernatants, from control and infected cells, were assayed 24 h later for PGE2 secretion by ELISA. Data are expressed as mean T standard deviation of three independent experiments performed in triplicates.
Fig. 2. COX-2 expression in RSV-infected alveolar epithelial cells. (A)
Northern blot. A549 cells were infected with RSV for various lengths of time. Total RNA was extracted from control and infected cells, and twenty micrograms of RNA was fractionated on a 1.2% agarose -formaldehyde gel, transferred to nylon membrane, and hybridized to a radiolabeled COX-2 cDNA probe. Membrane was stripped and reprobed with h-actin to verify equal loading of the samples. (B) Western blot. Total cell lysates were prepared from control and A549 cells infected for various lengths of time, fractionated on a 10% SDS-PAGE, transferred to PVDF membranes, and probed with the appropriate antibody. Membrane was stripped and reprobed with h-actin to verify equal loading of the samples. (C) Q-RT-PCR. A549 cells were infected with RSV for 24 h in the presence or absence of 20 AM cycloheximide. Total RNA was extracted from control and infected cells, and COX-2 mRNA levels were analyzed by real-time PCR. Signals were normalized to 18S RNA (see Materials and methods). Values are expressed as fold increase over control cells.
Based on the results of this experiment, we decided to investigate cPLA 2 activation following RSV infection. In unstimulated cells, cPLA 2 resides mainly in the cytoplasm but upon stimulation translocates to the membrane compartment to release AA. To determine whether RSV infection was able to increase cPLA 2 activity, A549 were infected with RSV for various lengths of time and harvested to prepare cytosolic and membrane fractions. cPLA 2 activity in both fractions was determined by quantification of the amount of free radiolabeled AA released from sn-2-[ 14 C]-arachidonyl phosphatidyl-ethanolamine. As shown in Fig. 5A , membrane fractions of RSVinfected cells showed a time-dependent induction of cPLA 2 activity, with a three-fold increase at 12 and 24 h p.i., a kinetic similar to the time course of AA release from infected radiolabeled cells (Fig. 3 ). There was no significant change of cPLA 2 activity in the cytosolic fraction of infected cells (data not shown).
To investigate cPLA 2 membrane translocation, following RSV infection, we performed Western blot analysis of cytosolic and membrane proteins. There was a timedependent increase in cPLA 2 abundance in the membrane fraction, which was paralleled by a decrease in cytosolic protein abundance (Fig. 5B ). These data confirm cPLA 2 activation following RSV infection.
Inhibition of cPLA 2 and COX-2 induction affects RSV replication and viral-induced cellular responses
Most viruses modify the host cellular environment in order to maximize their replication. Since PGE2 production has been shown to affect replication of other viruses, often resulting in enhanced infection, we investigated whether inhibition of COX-2 or the upstream activator cPLA 2 would modify RSV replication in alveolar epithelial cells. A549 were infected with RSV in the presence or absence of either 50 AM celecoxib or 25 AM pyrrophenone, and viral titers were determined 48 h post-infection. Production of infectious particles, defined as pfu/ml, was significantly decreased by both celecoxib and pyrrophenone treatment ( Table 1) , indicating that PGE2 plays an important role in RSV replication. Vehicle treatment slightly reduced cell viability (a decrease of¨5 -10% in DMSO-treated cells versus untreated, data not shown) without significantly reducing the amount of virus released by infected cells. Similar results were obtained when the inhibitors were added at the end of viral adsorption to the cells (data not shown). To determine whether reduced viral replication was in part due to inhibition of viral transcription, we assessed RSV N protein gene expression in A549 cells infected with RSV in the presence of either 50 AM celecoxib or 25 AM pyrrophenone. As shown in Fig. 6 , a 1.1 kb RSV N transcript was strongly present in A549 cells infected with RSV at 12 h p.i., and it was reduced more than 90% by pyrrophenone treatment (panel A) and 70 -80% by celecoxib treatment (panel B), indicating that PG production is necessary for efficient viral replication.
We have previously shown that RSV infection of A549 cells induces increased production of chemokines, important proinflammatory mediators, in a dose-and time-dependent manner, which requires viral replication (Olszewska- Pazdrak et al., 1998; Zhang et al., 2001) . To determine whether inhibition of RSV-induced COX-2 activation affected chemokine production from infected epithelial cells, we investigated CC and CXC chemokine mRNA steady-state levels in A549 cells infected with RSV for 12 h, in the absence or presence of celecoxib. RANTES and MCP-1, prototypes of CC chemokines, as well as IL-8, a prototype of CXC chemokine, were highly induced by RSV infection and significantly reduced by the COX-2 inhibitor (Figs. 7A and B) . Similarly, RANTES and IL-8 protein secretion were also significantly inhibited by celecoxib treatment, as shown in Fig. 7C . Membrane proteins were prepared from control and A549 cells infected for various lengths of time and assayed for PLA 2 enzymatic activity, as described in Materials and methods. (B) Western blot. Cytoplasmic and membrane proteins were prepared from control and A549 cells infected for various lengths of time, fractionated on a 10% SDS-PAGE, transferred to PVDF membranes, and probed with anti-cPLA 2 antibody. Membranes were stripped and reprobed with either h-actin or h-catenin to verify equal loading of the samples. In the past few years, we have characterized the mechanisms involved in RSV-induced expression of the chemokines IL-8 and RANTES Casola et al., 2000 Casola et al., , 2001b . Gene transcription of both chemokines is dependent on an intact nuclear factor (NF)-nB signaling pathway, as we and others have previously shown Casola et al., 2001b; Tian et al., 2002) . RSV-induced RANTES expression is also dependent on the activation of interferon regulatory factors (IRFs) which are absolutely necessary for RANTES gene transcription Casola et al., 2001b) . To investigate whether COX-2 inhibition would affect NF-nB and IRF activation, we infected A549 cells with RSV in the presence or absence of celecoxib, and we determined the abundance of DNA-binding proteins recognizing either the IL-8 NF-nB site or the RANTES IRF binding site (also known as ISRE). As shown in Fig. 8 , induction of the nucleoprotein complex formed on the ISRE probe, following RSV infection, was completely abrogated by celecoxib treatment, while the complex formed on the NF-nB probe was reduced by 70%, in agreement with the reduced IL-8 and RANTES gene expression and protein secretion observed, following inhibition of COX-2.
Discussion
RSV is the leading cause of epidemic respiratory tract illness in children in the US and worldwide. In infants and young children, RSV is the most common etiologic agent of bronchiolitis, a syndrome characterized by wheezing, dyspnea, respiratory distress, and the radiological evidence of hyperaeration of the lung. RSV infection does not induce protective immunity, resulting in repeat attacks of acute respiratory tract illness through adulthood. Indeed, RSV infection has been shown to inhibit mononuclear cell responses, as well as lymphocyte proliferation (Franke et al., 1995; Keles et al., 1999) . In addition to acute morbidity, there are long-term consequences of RSV infection in infancy. RSV has been shown to predispose to the development of hyperreactive airway disease, and recurrent episodes of wheezing in asthmatic children are often precipitated by RSV infection (Holberg et al., 1991; Stein et al., 1999; Sly and Hibbert, 1989) . In prospective studies, RSV bronchiolitis has been demonstrated to be the dominant risk factor among those known or suspected to influence the development of asthma (Sigurs et al., 1995) .
PGE2 is a small lipid molecule known to modulate immune functions (reviewed in Phipps et al., 1991) . It inhibits T-cell proliferation, suppresses the proliferation of immature B-cells, and inhibits maturation of dendritic cells and their ability to present antigen. Furthermore, PGE2 has been implicated in the enhancement of T helper 2 (Th2)type responses, implying a role for PGE2 in the development of allergy and asthma. It has been previously shown that RSV infection of macrophages and dendritic cells can induce PGE2 production (Midulla et al., 1993; Bartz et al., 2002) . Recently, alveolar epithelial cells, a target of RSV infection, have been shown to be an important source of PGE2 (Richardson et al., 2005) . However, the mechanism of RSV-induced PGE2 production and the role of PGE2 in RSV replication and intracellular signaling were not investigated.
Our results show that RSV is a potent inducer of PGE2 in alveolar epithelial cells and that viral replication is required for PGE2 secretion. These data are different from what has been previously shown in macrophages and dendritic cells, which both can secrete PGE2 following exposure to either live or UV-inactivated RSV (Bartz et al., 2002) . However, these results are in agreement with Richardson et al. study, showing that inactivation of RSV by UV exposure or pretreatment with palivizumab, an anti-RSV-F protein monoclonal antibody, completely blocks viral-induced PGE2 secretion. These data are also in agreement with our previous findings, showing that chemokine secretion and the signaling pathways leading to their expression, in RSVinfected epithelial cells, are dependent on viral replication (Olszewska- Pazdrak et al., 1998; Casola et al., 2001b) , indicating different requirements between epithelial cells and immune cells for triggering intracellular signals. RSV infection induces a time-dependent increase of COX-2 mRNA expression and protein synthesis, which is responsible for the enhanced PGE2 production in RSV-infected alveolar epithelial cells, as demonstrated by the use of celecoxib and NS398, specific COX-2 inhibitors that completely block RSV-induced PGE2 secretion. PGE2 production and COX-2 mRNA expression in A549 cells infected with RSV start at 6 h post-infection and increases up to 36 h, time after which cells begin to loose viability. This kinetic is different from the one recently published by Richardson et al., which showed no increase in either COX-2 or PGE2 in the first 24 h of infection. Possible explanations of our different findings are the use of a higher multiplicity of infection (MOI) of infection (we used an MOI of 3 to infect the majority of cells simultaneously) and the use of a different RSV strain (we used RSV A2 versus the Long strain used by Richardson) . Our kinetics of COX-2 expression, however, is similar to RSV induction of COX-2 in vivo, where significant COX-2 mRNA accumulation was seen in the lungs of infected cotton rats starting at 6 h postinfection (Richardson et al., 2005) . We also demonstrate that RSV-induced COX-2 expression is dependent on viral replication but does not require either viral or cellular protein synthesis since inhibition of protein translation does not block COX-2 induction following RSV infection. The observed enhancement of COX-2 mRNA levels by the presence of cycloheximide is a phenomenon well described for several genes including TNF, IL-2, and IL-8, due to various mechanisms including stabilization of mRNA transcripts, inhibition of transcriptional repressors, and posttranslational modification of transcriptional activators (Efrat et al., 1984; Osipovich et al., 1993; Roger et al., 1998) . Our result is in contrast with the findings of Richardson et al., showing that soluble factors, including IL-1 and TNF, are responsible for COX-2 induction following RSV infection (Richardson et al., 2005) . Their conclusions, however, are based on COX-2 induction following incubation of A549 cells with culture supernatants of epithelial cells infected with RSV for 48 h, treated with neutralizing antibodies for various cytokines. They did not attempt to block cytokine activity in the contest of active RSV replication. We have previously shown that UV-inactivated cell supernatant of early RSV infection (12 h post-infection), which contains little amount of soluble mediators, does not induce chemokine secretion and transcription factor activation in A549 cells , while cell supernatants of late RSV infection (48 h), which contains high amounts of cytokines and interferons, can induce gene expression and cellular activation similar to the virus itself (Jamaluddin et al., 2001 and A. Casola, personal communication) .
The production of PG begins with the release of arachidonic acid from membrane phospholipids by PLA 2 . Based on cellular localization, PLA 2 enzymes can be classified in two isoforms, secretory and cytosolic. The cytosolic PLA 2 s can then be divided in two categories, based on the requirement of calcium for the enzymatic activity: the intracellular Ca 2+ -dependent PLA 2 (cPLA 2 ) and the intracellular Ca 2+ -independent PLA 2 (iPLA 2 ) (reviewed in Steer et al., 2003; Balsinde et al., 1999) . The results of our study indicate that cPLA 2 is involved in RSV-induced PGE2 production, as indicated by the almost complete inhibition of PGE2 secretion following airway epithelial cell treatment with pyrrophenone, a novel compound whose inhibitory activity of cPLA 2 function is two to three orders of magnitude higher compared to the inhibitory activity of the other PLA 2 s (Ono et al., 2002; Seno et al., 2000) . A growing amount of evidence has indicated that cPLA 2 a contributes directly to the biosyn-thesis of eicosanoids by releasing arachidonic acid from membrane phospholipids and is associated with various inflammatory lung diseases, based on experiments using cPLA 2 a-deficient mice (Sapirstein and Bonventre, 2000) . In these mice, eicosanoid synthesis from inflammatory cells decreases significantly, as do allergic symptoms and acute lung injury induced by sepsis syndrome, indicating the contribution of cPLA 2 a to eicosanoid synthesis, leading to progression of inflammation and acute lung injury (Nagase et al., 2000; Uozumi et al., 1997) .
RSV infection of A549 cells induces cPLA 2 membrane translocation and enzymatic activity starting at early time points of infection. This is the first report that RSV activates cPLA 2 . Influenza virus infection of airway epithelial cells has also been shown to induce PGE2 production and cPLA 2 phosphorylation, a post-transcriptional modification that enhances cPLA 2 enzymatic activity (Mizumura et al., 2003) . However, that study did not show directly cPLA 2 activation and did not investigate its role in PG production. Previous studies have shown that cPLA 2 is present in the cytosol of resting cells and translocates to intracellular membranes following stimulation with a variety of agents (reviewed in Gijon and Leslie, 1999) . The nuclear envelope has often been reported as the major membrane compartment to which cPLA 2 relocates. In our study, we did not see increased cPLA 2 enzymatic activity or protein translocation to the nuclear membrane following RSV infection, indicating that cPLA 2 is more likely associated with the endoplasmic reticulum or Golgi apparatus, as recently shown in A549 cells stimulated with the calcium ionophore A23187 (Grewal et al., 2003) .
PGE2 production has been shown to be important for efficient replication of a variety of RNA and DNA viruses. In our study, inhibition of PGE2 production, by blocking either COX-2 or cPLA 2 activation, caused a significant reduction in RSV replication, indicating that PGE2 is required for effective RSV infection of airway epithelial cells. Our result is in contrast with the recently published study by Richardson et al., in which inhibition of COX-2 did not produce changes in viral replication, either in vitro or in vivo (Richardson et al., 2005) . Previous studies have shown that PGE2 production can affect various steps of viral replication, usually following virus cellular entry. Inhibition of PGE2 production or addition of exogenous PGE2 has been shown to modulate viral genome replication/ transcription (Allal et al., 2004; Symensma et al., 2003) , protein synthesis (Rossen et al., 2004; Ray et al., 2004) , as well as virus assembly (Ray et al., 2004) . Our study suggests that blocking either cPLA 2 or COX-2 activity during RSV infection leads to a significant inhibition of RNA transcription, as indicated by the greatly reduced amount of N gene transcript, although we cannot exclude an effect on virus uncoating. It is also possible that PGE2 affects other steps of RSV replication, which will require further investigation in order to be defined. Interestingly, a different member of the prostaglandin family, PGI2, has been show to have an antiviral effect in an in vivo model of RSV infection (Hashimoto et al., 2004) . Mice overexpressing PGI2 are protected against RSV-induced lung disease and have decreased peak viral titers, suggesting that different eicosanoids may play a different role in viral replication (Hashimoto et al., 2004) .
Inhibition of viral replication is the likely explanation for the significant reduction we observed in chemokine gene expression in airway epithelial cells treated with celecoxib. We have previously shown that viral replication is necessary for RSV-induced transcription of the chemokines IL-8 and RANTES, as well as for activation of NF-nB and IRF transcription factors Casola et al., 2000 Casola et al., , 2001b . However, we cannot exclude a direct role of AA or eicosanoids, produced during cPLA 2 or COX-2 activation, in RSV-induced cellular signaling. AA release has been shown to be an important mediator for activation of a variety of transcription factors, including AP-1, NF-nB, and STATs (Becuwe et al., 2003; Yellaturu and Rao, 2003) . Inhibition of chemokine and other RSVinduced proinflammatory molecules, by targeting either cPLA 2 or COX-2 activation, could be beneficial in ameliorating RSV-induced lung inflammation and clinical disease, as suggested by the finding that treatment of cotton rats with indomethacin, a nonspecific COX-2 inhibitor, significantly reduces RSV-induced peribronchial and perivascular inflammatory infiltrates, as well as interstitial pneumonitis and alveolitis (Richardson et al., 2005) . Additional studies are needed to better define the role of cPLA 2 and COX-2 activation in RSV-induced lung inflammatory and immune responses, as potential targets for treatment of RSV-induced lung disease.
Materials and methods
Reagents
Antibodies recognizing 85 kDa cPLA 2 , h-actin, hcatenin, and the peroxidase-conjugated anti-rabbit and anti-goat secondary antibodies were purchased from Santa Cruz Biotech, Santa Cruz, CA. Antibody to COX-2 was obtained from Cayman Chemical Company, Ann Arbor, MI. The chemical inhibitors cycloheximide, bromophenacyl bromide (BPB), methyl arachidonyl fluorophosphonate (MAPF), pyrrophenone (PP), indomethacin, celecoxib, and NS398 were purchased from Calbiochem-EMD Bioscience Inc., San Diego, CA. Protease Inhibitor Cocktail was purchased from Sigma.
RSV preparation
The RSV A2 strain was grown in Hep-2 cells and purified by centrifugation on discontinuous sucrose gradients as described elsewhere (Ueba, 1978) . The virus titer of the purified RSV pools was 8 -9 log 10 plaque forming units (PFU)/ml using a methylcellulose plaque assay. No contaminating cytokines were found in these sucrosepurified viral preparations (Patel et al., 1995) . LPS, assayed using the limulus hemocyanin agglutination assay, was not detected. Virus pools were aliquoted, quick-frozen on dry ice/alcohol, and stored at À70 -C until used.
Cell culture and infection of epithelial cells with RSV A549, human alveolar type II-like epithelial cells (from ATCC, Manassas, VA), were maintained in F12K medium containing 10% (v/v) FBS, 10 mM glutamine, 100 IU/ml penicillin, and 100 Ag/ml streptomycin. Cell monolayers were infected with RSV at MOI of 3 (unless otherwise stated), as described . An equivalent amount of a 30% sucrose solution was added to uninfected A549 cells as a control. For simplicity, uninfected cells are identified as ''control'' cells throughout the text and in the figures. When inhibitors were used, A549 cells were pretreated for 1 h with the inhibitors and then infected with RSV in the presence of the inhibitors. When inhibitors were diluted in DMSO, equal amounts of vehicle were added to untreated cells as a control. Total number of cells, cell viability, and viral replication, following treatment, were measured by trypan blue exclusion and by plaque assay, respectively. We did not observe cellular toxicity/cell death at any of the inhibitors concentration used for the described experiments.
ELISAs
Immunoreactive PGE2, IL-8, and RANTES were measured by double antibody ELISA kits (R&D Systems, Minneapolis, MN) following the manufacturer's protocol.
Western blotting
RSV-infected and control cells were lysed by adding icecold lysis buffer (50 mM Tris -HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 0.25% sodium deoxycholate, 1 mM Na 3 VO 4 , 1 mM NaF, 1% Triton X-100, and 1 Ag/ml of aprotinin, leupeptin, and pepstatin). After incubation on ice for 10 min, the lysates were collected, and detergent insoluble materials were removed by centrifugation at 4 -C at 14,000 Â g. Cell lysates (50 Ag per sample) were then boiled in 2Â Laemmli buffer for 2 min and resolved on SDS-PAGE. Proteins were transferred for 6 h onto Hybond-ECL nitrocellulose membrane (Amersham Pharmacia Biotech), and nonspecific binding sites were blocked by immersing the membrane in blocking solution TBS -Tween (TBST, 10 mM Tris -HCl, pH 7.6, 150 mM NaCl, 0.05% Tween-20) containing 5% skim milk powder for 30 min. After short wash in TBST, the membranes were incubated with the primary antibody overnight at 4 -C, followed by the peroxidase-conjugated secondary antibody, diluted 1:10,000 in TBST for 30 min at room temperature. After washing, proteins were detected using ECL (Amersham Pharmacia Biotech) according to manufacturer's protocol.
Northern blot
Total RNA was extracted from control and infected A549 cells by the acid guanidium thiocyanate-phenol chloroform method (Chomczynski and Sacchi, 1987) . Twenty micrograms of RNA was fractionated on a 1.2% agaroseformaldehyde gel, transferred to nylon membranes, and hybridized to a radiolabeled RSV N cDNA (Liu et al., 2004) or COX-2 cDNA (a generous gift of Dr. R. Mifflin, UTMB, Galveston, TX), as previously described (Casola et al., 2001b) . After washing, membranes were exposed for autoradiography using Kodak XAR film at À70 -C, using intensifying screens. After exposure, membranes were stripped and rehybridized with a h-actin probe. For COX-2 quantitative real-time PCR (Q-RT-PCR), Applied Biosystems assays-on-demand 20Â mix of primers and Taq-Man MGB probes (FAM-dye labeled) for target genes and 18S rRNA (VIC-dye labeled probe) TaqMan assay reagent (P/N 4319413E) for controls were used. Separate tubes (singleplex) one-step RT-PCR was performed with 80 ng RNA for both target genes and endogenous control. The cycling parameters for one-step RT-PCR were: reverse transcription 48 -C for 30 min, AmpliTaq activation 95 -C for 10 min, denaturation 95 -C for 15 s, and annealing/ extension 60 -C for 1 min (repeat 30 times) on ABI7000. Duplicate CT values were analyzed in Microsoft Excel using the comparative CT (DDCT) method as described by the manufacturer (Applied Biosystems). The amount of target (2 ÀDDCT ) was obtained by normalizing to endogenous reference (18S) sample.
[ 3 H]Arachidonic acid release
Cells were grown to confluency in 24-well plates and labeled in serum-free medium supplemented with 0.5 ACi [ 3 H]arachidonic acid overnight. Radioactive medium was then discarded, cells were washed several times with serumfree medium and infected with RSV. At different times postinfection, cell supernatants were carefully collected to avoid cell disruption and assessed for [ 3 H]arachidonic acid release by liquid scintillation counting.
Preparation of cytosolic and membrane fractions
Control or RSV-infected A549 cells were rinsed twice with sterile PBS and digested with 1Â trypsin/EDTA, washed and centrifuged two times with cold Ca 2+ -and Mg 2+ -free Hank's Balanced Salt Solution HBSS (À). Cells were transferred to ice-cold homogenization buffer (50 mM Tris -HCl pH 8.0, 1 mM EDTA, 1 mM EGTA, 20% glycerol, freshly added 1 mM DTT, and Protease Inhibitor Cocktail 1:100 dilution). Cell suspensions were then disrupted by sonication on ice using Branson Sonicator (15 -20 second cycle for 4 cycles at 20% duty cycle). The sonicate was centrifuged for 5 min at 4 -C at 1000 Â g to remove unbroken cell and debris. This low speed supernatant, designated as crude homogenate, was subsequently centrifuged at 100,000 Â g at 4 -C for 1 h. The high speed supernatant was designated as cytosolic fraction. The high speed pellet, representing the membrane fraction, was washed several times with ice-cold buffer containing 0.9% NaCl to remove cytosolic protein contaminant and resuspended in 500 Al of ice-cold homogenization buffer containing 0.1% Triton X-100. The pellet was then sonicated on ice for 15 s for 4 cycles. The cytosol and membrane fractions were aliquoted and stored at À80 -C until used for PLA 2 assay. Protein concentration was determined using Protein Reagent, Bio-Rad, Hercules, CA.
Phospholipase A 2 assay cPLA 2 activity was assayed according to the method described by Neagos et al. (1993) by quantification of the amount of free radiolabeled AA hydrolyzed from sn-2-[ 14 C]-arachidonyl phosphatidyl-ethanolamine (52 mCi/ mmol; NEN, Dupont). 100,000 dpm for each sample was taken in a conical glass stoppered tube, evaporated to dryness under a stream of N 2 gas to completely remove organic solvent, suspended in ice-cold 50 mM Tris -HCl (pH 8.0) buffer, and sonicated for 2 -3 min to prepare micelle of liposomes and kept on ice. 400 to 500 Ag protein of either cytoplasmic or membrane fractions was added in 100 Al of assay buffer (50 mM Tris -HCL, pH 8.0, 0.5 mg/ ml BSA, 0.5 mM EDTA, 20% glycerol (vol/vol) 10.5 mM CaCl 2 ) and pre-incubated at 37 -C for 5 min. The reaction was started by addition of substrate followed by gentle vortexing and incubation for 15 min at 37 -C with constant gentle shaking. One milliliter of chloroform -methanol mixture (2:1, vol/vol), containing 1% acetic acid, was added to stop the reaction and immediately vortexed vigorously for 2 -3 min and then centrifuged at 2500 rpm for 5 min. After centrifugation, the lower chloroform phase containing the AA was transferred carefully into another tube without disturbing the upper phase and interphase. The remaining aqueous phase was washed with 0.5 ml chloroform: methanol mixture and the combined organic phase were evaporated to dryness under N 2 gas, and the tubes covered and kept at À20 -C. Free AA was separated by thin-layer chromatography on silica gel plates using a solvent system of heptane/isopropyl ether/acetic acid (15:10:1 v/v), and the corresponding radioactivity in each of the spots was determined by scintillation counting. In each assay, hydrolysis was corrected for that which occurred in the absence of added protein sample. Percent hydrolysis was determined by the free AA released, and PLA 2 activity expressed as dpm/mg protein/min. For each experiment, results from triplicate assays were averaged to yield a single value.
Ribonuclease protection assay (RPA)
Control or RSV-infected A549 were harvested at different time points for total RNA extraction. Chemokine mRNA expression was determined using the multiprobe template hCK-5 of the RiboQuant kit (Pharmingen, San Diego, CA), as previously described (Haeberle et al., 2004) . Briefly, the probe was labeled with a-[ 32 P]-UTP (3000 Ci/mmol, 10 ACi/ Al; Du Pont NEN Research Products, Boston, MA) using a T7 polymerase. After overnight hybridization with 2 Ag of total RNA and RNA digestion, the samples were treated with proteinase K -SDS mixture, extracted by phenol chloroform, ethanol-precipitated, and loaded on a sequencing gel. Gels were dried and exposed to XAR film for autoradiography or PhosphoImager cassette for quantitation.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts of uninfected and infected cells were prepared using hypotonic/nonionic detergent lysis, as previously described (Casola et al., 2000) . After normalization, nuclear proteins were used to bind to duplex oligonucleotides corresponding to either the RANTES ISRE or the IL-8 NF-nB binding sites, as previously described (Casola et al., 2000 (Casola et al., , 2001a . DNA-binding reactions contained 10-15 Ag nuclear proteins, 5% glycerol, 12 mM HEPES, 80 mM NaCl, 5 mM DTT, 5 mM Mg 2 Cl, 0.5 mM EDTA, 1 Ag of poly dI-dC, and 40,000 cpm of 32 Plabeled double-stranded oligonucleotide in a total volume of 20 Al. The nuclear proteins were incubated with the probe for 15 min at room temperature and then fractionated by 6% nondenaturing polyacrylamide gels (PAGE) in TBE buffer (22 mM Tris -HCl, 22 mM boric acid, 0.25 mM EDTA, pH 8). After electrophoretic separation, gels were dried and exposed for autoradiography using Kodak XAR film at À70 -C using intensifying screens.
